Nowadays, biotech headlines usually talk about hundred million series A financings, oversubscribed IPOs, or multi-billion exits. But success is not guaranteed at all, even when throwing huge sums at a problem. Because biology is difficult, complex and drug discovery just incredibly hard and full of uncertainties. So it is very refreshing to have here an article where someone is also talking about the other side of the story when things do not go as planned. Take a look at the Endpoints News article so you can also get some learnings.
Read the full article here.
